| Tedi Begaj, MD | |
|
3555 W 13 Mile Rd Ste Ll-20, Royal Oak, MI 48073-6710 | |
| (248) 288-2280 | |
| Not Available |
| Full Name | Tedi Begaj |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 7 Years |
| Location | 3555 W 13 Mile Rd Ste Ll-20, Royal Oak, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003348905 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207WX0107X | Ophthalmology - Retina Specialist | 4301503908 (Michigan) | Secondary |
| 207W00000X | Ophthalmology | 4301503908 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beaumont Hospital Royal Oak | Royal oak, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associated Retinal Consultants Pc | 2264344746 | 28 |
| Beaumont Medical Group- Specialty Services | 7214299866 | 787 |
News Archive
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in its STARS clinical study.
Bruker Corporation and King Abdullah University of Science and Technology (KAUST) jointly announced the establishment of the Bruker Arabia office at the KAUST Research and Technology Park, furthering the trusted partnership between the two organizations.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma.
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.
› Verified 2 days ago
| Entity Name | Associated Retinal Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215003793 PECOS PAC ID: 2264344746 Enrollment ID: O20031103000637 |
News Archive
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in its STARS clinical study.
Bruker Corporation and King Abdullah University of Science and Technology (KAUST) jointly announced the establishment of the Bruker Arabia office at the KAUST Research and Technology Park, furthering the trusted partnership between the two organizations.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma.
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.
› Verified 2 days ago
| Entity Name | Associated Retinal Consultants Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215003793 PECOS PAC ID: 2264344746 Enrollment ID: O20031104000176 |
News Archive
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in its STARS clinical study.
Bruker Corporation and King Abdullah University of Science and Technology (KAUST) jointly announced the establishment of the Bruker Arabia office at the KAUST Research and Technology Park, furthering the trusted partnership between the two organizations.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma.
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.
› Verified 2 days ago
| Entity Name | Beaumont Medical Group- Specialty Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578072906 PECOS PAC ID: 7214299866 Enrollment ID: O20180320002549 |
News Archive
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in its STARS clinical study.
Bruker Corporation and King Abdullah University of Science and Technology (KAUST) jointly announced the establishment of the Bruker Arabia office at the KAUST Research and Technology Park, furthering the trusted partnership between the two organizations.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma.
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Tedi Begaj, MD 2000 N Huron River Dr Ste 100, Ypsilanti, MI 48197-1600 Ph: (248) 319-0161 | Tedi Begaj, MD 3555 W 13 Mile Rd Ste Ll-20, Royal Oak, MI 48073-6710 Ph: (248) 288-2280 |
News Archive
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced the successful completion of patient enrollment in its STARS clinical study.
Bruker Corporation and King Abdullah University of Science and Technology (KAUST) jointly announced the establishment of the Bruker Arabia office at the KAUST Research and Technology Park, furthering the trusted partnership between the two organizations.
Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.
Using a computer algorithm, scientists at Uppsala University have identified a promising new treatment for neuroblastoma.
Adding the anti-platelet drug clopidogrel to aspirin for the emergency treatment of heart attacks could save thousands of lives a year worldwide and prevent thousands of repeat heart attacks and strokes, according to new research presented at the American College of Cardiology annual conference.
› Verified 2 days ago
Dr. Robert J Mcdonald, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 32000 Woodward Ave, Royal Oak, MI 48073 Phone: 248-549-6000 Fax: 248-549-4923 | |
Huiyan Jin, Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3535 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-3643 | |
Dr. Sahal H. Saleh, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd, Royal Oak, MI 48073 Phone: 248-551-3000 | |
Dr. George R Lesser, MD Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 3535 W 13 Mile Rd, Suite 645, Royal Oak, MI 48073 Phone: 248-220-5252 Fax: 248-220-5261 | |
Dr. Tarek Shawky Hassan, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 3555 W 13 Mile Rd, Ll-20, Royal Oak, MI 48073 Phone: 248-288-2280 Fax: 248-288-5644 | |
Dr. Safa Arfeen, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 3601 W 13 Mile Rd Ofc, Royal Oak, MI 48073 Phone: 248-551-6347 |